These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 16775978)

  • 1. [HIV drug resistance].
    Marcelin AG; Calvez V
    Rev Prat; 2006 May; 56(9):978-86. PubMed ID: 16775978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of antiretroviral resistance on response in treatment-experienced patients.
    Kuritzkes DR
    AIDS Read; 2003 Dec; 13(12 Suppl Antiretroviral):S5-11. PubMed ID: 19967805
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Epidemiology of primary drug resistance in chronically HIV-infected patients in Nordrhein-Westfalen, Germany, 2001-2005].
    Oette M; Kaiser R; Däumer M; Fätkenheuer G; Rockstroh JK; Knechten H; Mitrenga D; Beerenwinkel N; Sagir A; Pfister H; Häussinger D
    Dtsch Med Wochenschr; 2007 May; 132(18):977-82. PubMed ID: 17457780
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiretroviral drug resistance and resistance testing.
    Gallant JE
    Top HIV Med; 2005 Dec-2006 Jan; 13(5):138-42. PubMed ID: 16377851
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV resistance testing. A clinical tool.
    Paul SM; Jorden VS
    N J Med; 2003 Sep; 100(9 Suppl):44-9; quiz 75-6. PubMed ID: 14556603
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV-1 pol phylogenetic diversity and antiretroviral resistance mutations in treatment naïve patients from Central West Brazil.
    Cardoso LP; Queiroz BB; Stefani MM
    J Clin Virol; 2009 Oct; 46(2):134-9. PubMed ID: 19682948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Boosted protease inhibitor-based or nonnucleoside reverse transcriptase-based HAART: is there a best choice for antiretroviral-naive HIV-1 infected patients?
    Cuzin L; Allavena C; Morlat P; Dellamonica P
    AIDS Rev; 2008; 10(4):205-11. PubMed ID: 19092976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evolution of drug resistance in HIV-infected patients remaining on a virologically failing combination antiretroviral therapy regimen.
    Cozzi-Lepri A; Phillips AN; Ruiz L; Clotet B; Loveday C; Kjaer J; Mens H; Clumeck N; Viksna L; Antunes F; Machala L; Lundgren JD;
    AIDS; 2007 Mar; 21(6):721-32. PubMed ID: 17413693
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic diversity and drug resistance mutations in HIV type 1 from untreated patients in Bamako, Mali.
    Derache A; Traore O; Koita V; Sylla A; Tubiana R; Simon A; Canestri A; Carcelain G; Katlama C; Calvez V; Cisse M; Marcelin AG
    Antivir Ther; 2007; 12(1):123-9. PubMed ID: 17503757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV drug resistance transmission threshold survey in Bangkok, Thailand.
    Sirivichayakul S; Phanuphak P; Pankam T; O-Charoen R; Sutherland D; Ruxrungtham K
    Antivir Ther; 2008; 13 Suppl 2():109-13. PubMed ID: 18575199
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of drug resistance algorithms and genotypic inhibitory quotient in prediction of lopinavir-ritonavir treatment response in human immunodeficiency virus type 1 protease inhibitor-experienced patients.
    Maillard A; Chapplain JM; Tribut O; Bentué-Ferrer D; Tattevin P; Arvieux C; Michelet C; Ruffault A
    J Clin Virol; 2007 Feb; 38(2):131-8. PubMed ID: 17208042
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term immunologic and virologic responses in patients with highly resistant HIV infection who are treated with an incompletely suppressive antiretroviral regimen.
    Gandhi T; Nagappan V; Cinti S; Wei W; Kazanjian P
    Clin Infect Dis; 2007 Oct; 45(8):1085-92. PubMed ID: 17879930
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails.
    Sungkanuparph S; Manosuthi W; Kiertiburanakul S; Piyavong B; Chumpathat N; Chantratita W
    Clin Infect Dis; 2007 Feb; 44(3):447-52. PubMed ID: 17205457
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV-1 drug resistance mutations in children who failed non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy.
    Sungkanuparph S; Apiwattanakul N; Thitithanyanont A; Chantratita W; Sirinavin S
    Southeast Asian J Trop Med Public Health; 2009 Jan; 40(1):83-8. PubMed ID: 19323038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ability of different lopinavir genotypic inhibitory quotients to predict 48-week virological response in highly treatment-experienced HIV-infected patients receiving lopinavir/ritonavir.
    Gianotti N; Galli L; Danise A; Hasson H; Boeri E; Lazzarin A; Castagna A
    J Med Virol; 2006 Dec; 78(12):1537-41. PubMed ID: 17063520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug-class-wide resistance to antiretrovirals in HIV-infected patients failing therapy: prevalence, risk factors and virological outcome.
    Tozzi V; Zaccarelli M; Bonfigli S; Lorenzini P; Liuzzi G; Trotta MP; Forbici F; Gori C; Bertoli A; Bellagamba R; Narciso P; Perno CF; Antinori A;
    Antivir Ther; 2006; 11(5):553-60. PubMed ID: 16964822
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary drug resistance in antiretroviral-naïve injection drug users.
    Tossonian HK; Raffa JD; Grebely J; Viljoen M; Mead A; Khara M; McLean M; Krishnamurthy A; DeVlaming S; Conway B
    Int J Infect Dis; 2009 Sep; 13(5):577-83. PubMed ID: 19111493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Threshold survey evaluating transmitted HIV drug resistance among public antenatal clinic clients in Addis Ababa, Ethiopia.
    Abegaz WE; Grossman Z; Wolday D; Ram D; Kaplan J; Sibide K; Wuhib T; Ismael S; Nkengasong J; Mekonen T; Berhanu H; Messele T; Lulseged S; Maayan S; Mengistu Y
    Antivir Ther; 2008; 13 Suppl 2():89-94. PubMed ID: 18575196
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence and impact of HIV-1 protease codon 33 mutations and polymorphisms in treatment-naive and treatment-experienced patients.
    Kozal MJ; Hullsiek KH; Leduc R; Novak RM; MacArthur RD; Lawrence J; Baxter JD;
    Antivir Ther; 2006; 11(4):457-63. PubMed ID: 16856619
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of peripheral blood DNA for genotype antiretroviral resistance testing in drug-naive HIV-infected subjects.
    Vicenti I; Razzolini F; Saladini F; Romano L; Zazzi M
    Clin Infect Dis; 2007 Jun; 44(12):1657-61. PubMed ID: 17516412
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.